Clinical Trials
3 trialsNCT06444880 2026-06-04
Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06528769 2025-09-30
Study of All-Trans Retinoic Acid (ATRA) and Cemiplimab in Patients With Advanced Leiomyosarcoma
Ohio State University Comprehensive Cancer Center
Phase 2 Recruiting
NCT05864144 2025-08-15
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Sensei Biotherapeutics, Inc.
Phase 1/2 Active not recruiting